Europe's Ariane 6 blasts off on first flight-February 2024-www.financetom.com

Europe's Ariane 6 blasts off on first flight

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Europe's Ariane 6 blasts off on first flight

Jul 9, 2024 12:19 PM

PARIS, July 9 (Reuters) - Europe's Ariane 6 launch

blasted off successfully on Tuesday on its maiden flight, a live

video feed showed.

Weighing 540 tonnes and standing 56 metres tall, Europe's

newest rocket left the launchpad in French Guiana around 4 p.m.

local time (1900 GMT) at the start of a nearly three-hour flight

designed to end a year-long hiatus in European access to space.

Previous page： Top Premarket Decliners Next page： Oncolytics Biotech Doses First Patient in Pelareorep Study Involving Modified FOLFIRINOX

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Top Premarket Decliners

Jun 20, 2024

07:54 AM EDT, 06/20/2024 (MT Newswires) -- 908 Devices ( MASS ) shares slumped 18% Thursday premarket following a 3.5% drop in the previous session. Actelis Networks ( ASNS ) shares fell 17%, paring Tuesday's rally. La Rosa Holdings ( LRHC ) shares were down 16%, shaving gains from the previous session. Kaival Brands Innovation (KAVL) shares dropped 15%, reversing...

Oncolytics Biotech Doses First Patient in Pelareorep Study Involving Modified FOLFIRINOX

Jun 20, 2024

07:53 AM EDT, 06/20/2024 (MT Newswires) -- Oncolytics Biotech ( ONCY ) on Thursday said it has dosed the first patient in the new GOBLET study cohort evaluating a pelareorep combination therapy involving modified FOLFIRINOX (mFOLFIRINOX) in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The therapy being assessed in this cohort may include the cancer immunotherapy treatment atezolizumab, Oncolytics...

Top Premarket Gainers

Jun 20, 2024

07:53 AM EDT, 06/20/2024 (MT Newswires) -- Tempest Therapeutics ( TPST ) shares surged more than 45% Thursday premarket after the company said Wednesday it will report fresh data from a phase 1b/2 trial of a combination treatment candidate for hepatocellular carcinoma. Molecular Partners ( MOLN ) shares rose 22%, adding to Tuesday's rise. Denali Capital Acquisition ( DECA )...

Jazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage study

Jun 20, 2024

June 20 (Reuters) - Jazz Pharmaceuticals ( JAZZ ) said on Thursday its experimental drug to treat a neurological condition that causes involuntary and rhythmic shaking failed to meet the main goal in a mid-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Mrigank Dhaniwala) ...